FIGURE 6.

Antitumor activities of BC-02 in vivo. 3 × 10⁶ H22 cells were injected to the enterocoelia of Kunming mice. Then, mice were divided into different groups and treated with BC-02 and capecitabine, and survival period was recorded (A). Capecitabine-resistant H22 cells was inoculated subcutaneously in KM mice, and they were treated with BC-02 and capecitabine. Then, mice body weight was monitored (D). After 2 weeks, all mice were sacrificed and dissected to weigh tumor tissues (B,C). “” means no tumor was found.